Research

Energy balance

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

GoodQualifiesHIGH confidence
Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI.
Longgang Xiang et al. · International Journal of Molecular Sciences · 2025

Why this rating

Mediation analysis using MR provides robust evidence for the pathway, though biological mechanisms remain to be fully elucidated.

Source

Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study

Longgang Xiang et al. · International Journal of Molecular Sciences · 2025

DOI 10.3390/ijms26062741

Meta-analysis · 2 studiesCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →